Table 5 Cardiovascular events (CVEs) before 5 years and after 5 years by Framingham risk category at baseline.
Framingham general risk of CVE < 10% | Framingham general risk of CVE ≥ 10% to <20% | Framingham general risk of CVE ≥ 20% | |||||||
|---|---|---|---|---|---|---|---|---|---|
Nilotinib 300 mg twice daily | Nilotinib 400 mg twice daily | Imatinib 400 mg once daily | Nilotinib 300 mg twice daily | Nilotinib 400 mg twice daily | Imatinib 400 mg once daily | Nilotinib 300 mg twice daily | Nilotinib 400 mg twice daily | Imatinib 400 mg once daily | |
CVEs occurring before 5 years | |||||||||
All patients, n | 178 | 176 | 182 | 41 | 52 | 49 | 40 | 38 | 33 |
All CVEs | 4 (2.2) | 7 (4.0) | 1 (0.5) | 5 (12.2) | 10 (19.2) | 2 (4.1) | 6 (15.0) | 11 (28.9) | 1 (3.0) |
Ischemic heart disease | 3 (1.7) | 5 (2.8) | 1 (0.5) | 3 (7.3) | 6 (11.5) | 1 (2.0) | 2 (5.0) | 5 (13.2) | 1 (3.0) |
Peripheral arterial occlusive disease | 1 (0.6) | 0 | 0 | 1 (2.4) | 1 (1.9) | 0 | 3 (7.5) | 5 (13.2) | 0 |
Ischemic cerebrovascular disease | 0 | 1 (0.6) | 0 | 1 (2.4) | 4 (7.7) | 1 (2.0) | 1 (2.5) | 1 (2.6) | 0 |
Other CVEs | 0 | 1 (0.6) | 0 | 1 (2.4) | 0 | 0 | 2 (5.0) | 1 (2.6) | 0 |
CVEs occurring after 5 years | |||||||||
Patients on treatment for > 5 years, n | 115 | 125 | 94 | 25 | 33 | 23 | 24 | 21 | 21 |
All CVEs | 10 (8.7) | 19 (15.2) | 1 (1.1) | 7 (28.0) | 16 (48.5) | 4 (17.4) | 8 (33.3) | 7 (33.3) | 1 (4.8) |
Ischemic heart disease | 4 (3.5) | 11 (8.8) | 1 (1.1) | 3 (12.0) | 7 (21.2) | 2 (8.7) | 2 (8.3) | 2 (9.5) | 1 (4.8) |
Peripheral arterial occlusive disease | 2 (1.7) | 6 (4.8) | 0 | 3 (12.0) | 3 (9.1) | 0 | 4 (16.7) | 6 (28.6) | 0 |
Ischemic cerebrovascular disease | 4 (3.5) | 6 (4.8) | 0 | 1 (4.0) | 7 (21.2) | 1 (4.3) | 2 (8.3) | 3 (14.3) | 0 |
Other CVEs | 0 | 0 | 0 | 0 | 1 (3.0) | 1 (4.3) | 0 | 1 (4.8) | 0 |
